These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

429 related items for PubMed ID: 17890266

  • 21. A drug safety evaluation of everolimus in kidney transplantation.
    Holdaas H, Midtvedt K, Åsberg A.
    Expert Opin Drug Saf; 2012 Nov; 11(6):1013-22. PubMed ID: 22954349
    [Abstract] [Full Text] [Related]

  • 22. Multidisciplinary insights on clinical guidance for the use of proliferation signal inhibitors in heart transplantation.
    Zuckermann A, Manito N, Epailly E, Fiane A, Bara C, Delgado JF, Lehmkuhl H, Ross H, Eisen H, Chapman J, Valantine H.
    J Heart Lung Transplant; 2008 Feb; 27(2):141-9. PubMed ID: 18267219
    [Abstract] [Full Text] [Related]

  • 23. Evaluation of the efficacy and safety of the conversion from a calcineurin inhibitor to an everolimus-based therapy in maintenance renal transplant patients.
    Sánchez Fructuoso A, Ruiz San Millán JC, Calvo N, Rodrigo E, Moreno MA, Cotorruelo J, Conesa J, Gómez-Alamillo C, Arias M, Barrientos A.
    Transplant Proc; 2007 Sep; 39(7):2148-50. PubMed ID: 17889120
    [Abstract] [Full Text] [Related]

  • 24. Avoidance of calcineurin inhibitors with use of proliferation signal inhibitors in de novo heart transplantation with renal failure.
    González-Vílchez F, de Prada JA, Exposito V, García-Camarero T, Fernández-Friera L, Llano M, Ruano J, Martín-Durán R.
    J Heart Lung Transplant; 2008 Oct; 27(10):1135-41. PubMed ID: 18926406
    [Abstract] [Full Text] [Related]

  • 25. Sirolimus--challenging current perspectives.
    Buhaescu I, Izzedine H, Covic A.
    Ther Drug Monit; 2006 Oct; 28(5):577-84. PubMed ID: 17038868
    [Abstract] [Full Text] [Related]

  • 26. Sirolimus for solid organ transplantation in children.
    Gupta P, Kaufman S, Fishbein TM.
    Pediatr Transplant; 2005 Jun; 9(3):269-76. PubMed ID: 15910380
    [Abstract] [Full Text] [Related]

  • 27. Sirolimus attenuates chronic allograft nephropathy in an experimental rat kidney transplantation model.
    Savikko J, von Willebrand E.
    Transplant Proc; 2006 Oct; 38(8):2699-700. PubMed ID: 17098043
    [Abstract] [Full Text] [Related]

  • 28. Potential role of proliferation signal inhibitors on atherosclerosis in renal transplant patients.
    Andrés V, Castro C, Campistol JM.
    Nephrol Dial Transplant; 2006 Jul; 21 Suppl 3():iii14-7. PubMed ID: 16815851
    [Abstract] [Full Text] [Related]

  • 29. Rationale for using belatacept in combination with sirolimus.
    Wéclawiak H, Kamar N, Ould-Mohamed A, Cardeau-Desangles I, Rostaing L.
    Transplant Proc; 2010 Nov; 42(9 Suppl):S29-31. PubMed ID: 21095447
    [Abstract] [Full Text] [Related]

  • 30. Use of proliferation signal inhibitors in the management of post-transplant malignancies--clinical guidance.
    Campistol JM, Albanell J, Arns W, Boletis I, Dantal J, de Fijter JW, Mortensen SA, Neumayer HH, Øyen O, Pascual J, Pohanka E, Schena FP, Serón D, Sparacino V, Chapman JR.
    Nephrol Dial Transplant; 2007 May; 22 Suppl 1():i36-41. PubMed ID: 17456617
    [Abstract] [Full Text] [Related]

  • 31. Experience with everolimus.
    Augustine JJ, Hricik DE.
    Transplant Proc; 2004 Mar; 36(2 Suppl):500S-503S. PubMed ID: 15041396
    [Abstract] [Full Text] [Related]

  • 32. Proliferation signal inhibitors in transplantation: questions at the cutting edge of everolimus therapy.
    Chapman JR, Valantine H, Albanell J, Arns WA, Campistol JM, Eisen H, Frigerio M, Lehmkuhl H, Marcen R, Morris R, Nashan B, Pascual J, Pohanka E, Segovia J, Zuckermann A.
    Transplant Proc; 2007 Dec; 39(10):2937-50. PubMed ID: 18089298
    [Abstract] [Full Text] [Related]

  • 33. Conversion from calcineurin inhibitors to sirolimus maintenance therapy in renal allograft recipients: 24-month efficacy and safety results from the CONVERT trial.
    Schena FP, Pascoe MD, Alberu J, del Carmen Rial M, Oberbauer R, Brennan DC, Campistol JM, Racusen L, Polinsky MS, Goldberg-Alberts R, Li H, Scarola J, Neylan JF, Sirolimus CONVERT Trial Study Group.
    Transplantation; 2009 Jan 27; 87(2):233-42. PubMed ID: 19155978
    [Abstract] [Full Text] [Related]

  • 34. Sirolimus as primary immunosuppressant for calcineurin inhibitor-related renal insufficiency after liver transplantation.
    Yang YJ, Li LX, He Q, Fan H, Jin ZK, Lang R, Kou JT, Li P, Xie DH, Chen DZ.
    Hepatobiliary Pancreat Dis Int; 2007 Aug 27; 6(4):376-8. PubMed ID: 17690032
    [Abstract] [Full Text] [Related]

  • 35. Immunosuppression using the mammalian target of rapamycin (mTOR) inhibitor everolimus: pilot study shows significant cognitive and affective improvement.
    Lang UE, Heger J, Willbring M, Domula M, Matschke K, Tugtekin SM.
    Transplant Proc; 2009 Dec 27; 41(10):4285-8. PubMed ID: 20005385
    [Abstract] [Full Text] [Related]

  • 36. Fifteen years of clinical studies and clinical practice in renal transplantation: reviewing outcomes with de novo use of sirolimus in combination with cyclosporine.
    Kahan BD.
    Transplant Proc; 2008 Dec 27; 40(10 Suppl):S17-20. PubMed ID: 19100899
    [Abstract] [Full Text] [Related]

  • 37. Late conversion from calcineurin inhibitor-based to sirolimus-based immunosuppression due to chronic toxicity: a prospective study with protocol biopsy amendment.
    Uslu A, Töz H, Sen S, Alkan FT, Nart A, Aykas A, Doğan M, Postaci H, Sahin T, Simşek C.
    Transplant Proc; 2009 Mar 27; 41(2):756-63. PubMed ID: 19328973
    [Abstract] [Full Text] [Related]

  • 38. mTOR inhibitors: an overview.
    Neuhaus P, Klupp J, Langrehr JM.
    Liver Transpl; 2001 Jun 27; 7(6):473-84. PubMed ID: 11443573
    [Abstract] [Full Text] [Related]

  • 39. Late conversion to mammalian target of rapamycin inhibitor/proliferation signal inhibitors in kidney transplant patients: clinical experience in the last 5 years.
    Sola E, Lopez V, Gutierrez C, Cabello M, Burgos D, Molina MG, Hernandez D.
    Transplant Proc; 2010 Oct 27; 42(8):2859-60. PubMed ID: 20970551
    [Abstract] [Full Text] [Related]

  • 40. Immunosuppressive strategies to improve outcomes of kidney transplantation.
    Tang IY, Meier-Kriesche HU, Kaplan B.
    Semin Nephrol; 2007 Jul 27; 27(4):377-92. PubMed ID: 17616271
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 22.